Results 111 to 120 of about 15,814 (215)

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Effects of Empagliflozin Combined with Anaerobic, Aerobic, and Endurance Swimming Protocols on Cardiac Structure and Electrophysiology in Healthy Rats. [PDF]

J Clin Med
Yavuz S, Kilic Ş, Asal S, Babaoglu M, Demirtaş C, Yildirim M, Altay S, Orhan AL.   +7 more
europepmc   +1 more source

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8230-8241, September 2026.
ABSTRACT Aim Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We
Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim   +7 more
wiley   +1 more source

Organ-Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. [PDF]

J Am Heart Assoc
Li J, Dai W, Alavi R, Carreno J, Arakaki X, Pahlevan NM, Kloner RA.   +6 more
europepmc   +1 more source

Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice. [PDF]

Front Microbiol
He J, Liu J, Zhang H, Wang Y.
europepmc   +1 more source

The effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit in diabetic kidney disease. [PDF]

Rev Assoc Med Bras (1992)
Karaköse S, Doğan B, Ergül F, Güney İ.   +3 more
europepmc   +1 more source

Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large‐Scale Propensity Score–Matched Real‐World Analysis

Clinical Cardiology, Volume 49, Issue 8, August 2026.
In this large real‐world propensity‐matched analysis, tirzepatide demonstrated superior reductions in mortality, hospitalizations, and cardiorenal outcomes versus dulaglutide in HFpEF patients, with a favorable safety profile. ABSTRACT Background No direct head‐to‐head trials compare tirzepatide and dulaglutide in heart failure with preserved ejection ...
Ibrahim Khalil, Md. Imran Hossain, Mst. Mahmuda Akter, Ferdous Wahid, Aizaz Anwar Khalid, Sunjida Amin Promi, Md. Abu Sayed, Mohd Turzo Rahman, Pallab Sarker   +8 more
wiley   +1 more source

Empagliflozin and renal histological changes in an experimental model of heart failure in male rats. [PDF]

Physiol Rep
Wisnivesky ACT, Bertacchi JGF, Caramelli B.   +2 more
europepmc   +1 more source

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source

Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review. [PDF]

Int J Gen Med
Wang X, Ning Y, Wang X, Li G, Wang X, Wu D.   +5 more
europepmc   +1 more source